Proactive research analyst John Savin speaks to Stephen Gunnion after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC).
The company has successfully completed dosing in a Phase 1a COVID study, marking a major milestone for any biotech firm. The key takeaway is the safety of the dosing, even at the highest levels, in healthy participants. NanoViricides (NYSE-A:NNVC) plans to advance to a Phase 1b study with actual COVID patients in India, where a surge in cases provides an opportune environment for clinical trials. This study focuses on a highly transmissible but not more dangerous COVID variant.
Savin highlights the company's broader ambitions to conduct trials for other viruses, demonstrating its versatile research capabilities. The financial aspect is also promising; NanoViricides (NYSE-A:NNVC) reported having about $7 million in cash for the half-year, with an additional over $2 million loan from the CEO, ensuring adequate funding for ongoing programs.
The therapy aims to reduce the viral load to prevent infection of healthy cells and to enable the immune system to clear viruses rapidly.